Detalhe da pesquisa
1.
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer.
Int J Radiat Oncol Biol Phys
; 116(4): 837-848, 2023 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36657497